| 摘要 |
The present invention discloses that prior art combination chemotherapy protocols for HER cancers (human epidermal growth factor receptor overexpression driven cancers) that employ concurrent administration of HER blockers and phase specific cell cycle active cytotoxics result in antagonistic action between the two classes of drugs in a manner that prevents function of all but the first administration of the phase specific cell cycle active chemotherapeutic. The present invention provides protocols that allow the two classes of chemotherapeutics to function synergistically. Prior art protocols also ignore endocrine dependence of HER cancers. The present invention discloses protocols for HER cancers that are also endocrine dependent in a manner that provides dual action by using both HER antibodies and endocrine blockers/downregulators and insures function of S-Phase cytotoxics by administration of endocrines prior to administration of the S-Phase cytotoxic.
|
